Amyloid Precursor C-Terminal Peptide Mechanisms, Clinical Ap

Amyloid Precursor C-Terminal Peptide: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Amyloid Precursor Protein (APP) is a transmembrane glycoprotein ubiquitously expressed in many tissues, with particularly high abundance in neuronal cells. The proteolytic processing of APP gives rise to several peptide fragments, among which the Amyloid Precursor C-Terminal Peptide (APP-CT or C99) has garnered significant attention in neurodegenerative disease research, especially Alzheimer’s disease (AD). The APP-CT peptide, typically comprising the last 99 amino acids of APP, is generated following β-secretase cleavage and serves as a substrate for γ-secretase, which subsequently produces amyloid-β (Aβ) peptides implicated in AD pathology (Haass et al., 2012, Nature Reviews Molecular Cell Biology). Understanding the biology and function of APP-CT is crucial for elucidating the molecular mechanisms underlying amyloidogenesis and for developing targeted therapeutic interventions.

The mechanism of action of the Amyloid Precursor C-Terminal Peptide is multifaceted. As an immediate precursor to Aβ, APP-CT is central to the amyloidogenic pathway. Its accumulation and subsequent processing by γ-secretase not only generate Aβ peptides but also release the APP intracellular domain (AICD), which has been implicated in nuclear signaling and gene regulation (Cao & Südhof, 2001, Science). The dual role of APP-CT in both amyloidogenesis and intracellular signaling positions it as a critical target for research into neurodegenerative disease mechanisms and potential therapeutic strategies.

Clinical Value and Applications
The clinical value of the Amyloid Precursor C-Terminal Peptide lies primarily in its relevance to Alzheimer’s disease and related neurodegenerative disorders. The accumulation of Aβ peptides, derived from APP-CT, is a hallmark of AD pathology, forming extracellular plaques that disrupt neuronal function and trigger neuroinflammation (Selkoe & Hardy, 2016, EMBO Molecular Medicine). By serving as a direct substrate for γ-secretase, APP-CT is pivotal in the generation of the pathogenic Aβ42 isoform, which is particularly prone to aggregation.

Research-grade APP-CT peptides are widely used as molecular tools in the following applications:
- **Elucidation of APP processing pathways:** By providing a defined substrate for γ-secretase assays, APP-CT peptides enable the study of enzyme kinetics, substrate specificity, and the effects of pharmacological modulators.
- **Screening of γ-secretase inhibitors:** APP-CT peptides are essential for high-throughput screening of small molecule inhibitors or modulators of γ-secretase, a key therapeutic target in AD (De Strooper, 2014, Cell).
- **Investigation of AICD-mediated signaling:** The release of AICD from APP-CT cleavage can be studied using synthetic peptides to dissect downstream gene regulatory mechanisms.
- **Modeling amyloidogenic processes:** APP-CT peptides facilitate in vitro and in vivo modeling of amyloidogenesis, supporting the development of disease models and the evaluation of candidate therapeutics.

Beyond Alzheimer’s disease, aberrant APP processing and APP-CT accumulation have been implicated in other neurodegenerative conditions, including cerebral amyloid angiopathy and Down syndrome, further underscoring the peptide’s clinical relevance (Wisniewski & Drummond, 2020, Frontiers in Neuroscience).

[Related: olaparib label] Key Challenges and Pain Points Addressed
Current research and therapeutic strategies targeting amyloidogenic pathways face several challenges:
- **Complexity of APP processing:** The sequential cleavage of APP by β- and γ-secretases generates multiple peptide fragments, complicating the analysis of specific intermediates and their roles in disease.
- **Lack of specific substrates:** Traditional approaches often rely on full-length APP or cell-based systems, which can introduce confounding variables and limit assay specificity.
- **Difficulty in isolating γ-secretase activity:** The membrane-bound nature of γ-secretase and its broad substrate specificity make it challenging to study in isolation.
- **Limited understanding of AICD function:** The biological roles of the AICD, released upon APP-CT cleavage, remain incompletely understood due to the transient nature of this fragment.

The availability of synthetic Amyloid Precursor C-Terminal Peptide addresses these pain points by providing a defined, high-purity substrate for biochemical assays. This enables precise dissection of γ-secretase activity, facilitates the development of specific inhibitors, and supports mechanistic studies of AICD-mediated signaling. Furthermore, the use of APP-CT peptides in experimental models helps to clarify the contributions of individual APP fragments to neurodegenerative processes.

Literature Review
A growing body of literature supports the central role of APP-CT in amyloidogenesis and neurodegeneration:
1. **Haass et al. (2012, Nature Reviews Molecular Cell Biology):** This review outlines the molecular mechanisms of APP processing, emphasizing the role of C-terminal fragments in the generation of pathogenic Aβ peptides and the importance of γ-secretase as a therapeutic target.
2. **Cao & Südhof (2001, Science):** The authors demonstrate that the AICD, released from APP-CT cleavage, translocates to the nucleus and regulates gene expression, suggesting a dual role for APP-CT in both amyloidogenesis and cellular signaling.
3. **De Strooper (2014, Cell):** This study discusses the challenges and opportunities in targeting γ-secretase, highlighting the utility of APP-CT peptides in screening for selective inhibitors that reduce Aβ production without affecting other substrates.
4. **Selkoe & Hardy (2016, EMBO Molecular Medicine):** The review provides an updated perspective on the amyloid hypothesis of AD, underscoring the pathogenic significance of Aβ derived from APP-CT and the need for improved experimental models.
5. **Wisniewski & Drummond (2020, Frontiers in Neuroscience):** The authors explore the broader implications of APP processing in neurodegenerative diseases beyond AD, including the role of APP-CT in cerebral amyloid angiopathy and Down syndrome.
6. **Sastre et al. (2001, Journal of Biological Chemistry):** This study investigates the role of APP-CT in apoptosis, demonstrating that overexpression of C-terminal fragments can induce cell death, providing insight into potential mechanisms of neurotoxicity.
7. **Gu et al. (2012, Journal of Neurochemistry):** The authors use synthetic APP-CT peptides to characterize γ-secretase activity in vitro, establishing a platform for high-throughput screening of modulators.

Collectively, these studies highlight the multifaceted roles of APP-CT in neurobiology and disease, and validate the use of synthetic peptides as essential research tools.

[Related: y27632 molecular weight] Experimental Data and Results
Experimental studies utilizing Amyloid Precursor C-Terminal Peptide have yielded important insights into APP processing and amyloidogenesis:
- **γ-Secretase Assays:** Synthetic APP-CT peptides have been employed as substrates in cell-free γ-secretase assays, enabling the quantification of Aβ production and the assessment of inhibitor efficacy. Gu et al. (2012) demonstrated that the use of purified APP-CT peptides allows for precise measurement of γ-secretase activity, facilitating the identification of selective modulators.
- **AICD Signaling Studies:** Cao & Südhof (2001) used APP-CT-derived peptides to show that AICD can translocate to the nucleus and interact with transcriptional coactivators, influencing the expression of genes involved in apoptosis and synaptic function.
- **Neurotoxicity Models:** Sastre et al. (2001) reported that overexpression or exogenous application of APP-CT fragments in neuronal cultures induces apoptotic cell death, supporting a potential role for C-terminal fragments in neurodegeneration.
- **Drug Screening:** High-throughput screening platforms using APP-CT peptides have enabled the rapid evaluation of γ-secretase inhibitors, with several candidate compounds demonstrating selective reduction of Aβ42 production (De Strooper, 2014).

These findings underscore the utility of APP-CT peptides in dissecting the molecular mechanisms of APP processing, modeling disease-relevant pathways, and supporting drug discovery efforts.

Usage Guidelines and Best Practices
To maximize the utility and reproducibility of experiments involving Amyloid Precursor C-Terminal Peptide, the following guidelines are recommended:
- **Peptide Preparation:** Synthetic APP-CT peptides should be reconstituted in sterile, buffered solutions (e.g., PBS or Tris-HCl) at concentrations appropriate for the intended assay. Peptide aliquots should be stored at -20°C or below to prevent degradation.
- **Assay Design:** For γ-secretase activity assays, use purified or membrane-bound enzyme preparations and include appropriate controls (e.g., known inhibitors, non-substrate peptides). Optimize peptide concentration to ensure substrate saturation without exceeding solubility limits.
- **Cellular Studies:** When using APP-CT peptides in cell culture, verify peptide uptake and localization. Consider using fluorescently labeled peptides for tracking and quantification.
- **Data Interpretation:** Distinguish between effects attributable to APP-CT versus downstream cleavage products [Related: aproptinin] Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 23 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11578956